Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
CRISPR Therapeutics AG CRSP
$64.23
-$1.73 (-2.70%)
На 18:00, 12 мая 2023
+103.47%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
5234725778.00000000
-
week52high
86.95
-
week52low
38.94
-
Revenue
436000
-
P/E TTM
-7
-
Beta
1.69965300
-
EPS
-8.18000000
-
Last Dividend
0.00000000
-
Next Earnings Date
21 февр 2023 г. в 21:01
Описание компании
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company's lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta-thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. It also develops CTX110, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting cluster of differentiation 19 positive malignancies; CTX120, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting B-cell maturation antigen for the treatment of relapsed or refractory multiple myeloma; and CTX130, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting Cluster of Differentiation 70 to treat various solid tumors and hematologic malignancies. In addition, the company develops VCTX210, a gene-edited immune-evasive stem cell-derived product candidate for the treatment of treatment of type 1 diabetes; and pursues various in vivo gene-editing programs that target the liver, lung, muscle, and central nervous system diseases. It has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| RBC Capital | Sector Perform | Sector Perform | 09 авг 2022 г. |
| Credit Suisse | Neutral | Neutral | 09 авг 2022 г. |
| Chardan Capital | Buy | Buy | 09 авг 2022 г. |
| Barclays | Equal-Weight | Overweight | 09 авг 2022 г. |
| Citigroup | Neutral | Neutral | 02 авг 2022 г. |
| Morgan Stanley | Underweight | 11 окт 2022 г. | |
| RBC Capital | Sector Perform | Sector Perform | 02 ноя 2022 г. |
| Credit Suisse | Neutral | Neutral | 02 ноя 2022 г. |
| SVB Leerink | Outperform | Outperform | 07 ноя 2022 г. |
| Citigroup | Neutral | Neutral | 23 ноя 2022 г. |
| EF Hutton | Buy | 05 янв 2023 г. | |
| JMP Securities | Market Outperform | Market Outperform | 19 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Kulkarni Samarth | D | 179582 | 25000 | 27 янв 2023 г. |
| Kulkarni Samarth | D | 369111 | 23200 | 27 янв 2023 г. |
| Kulkarni Samarth | D | 392311 | 1800 | 27 янв 2023 г. |
| Kulkarni Samarth | A | 394111 | 25000 | 27 янв 2023 г. |
| Kulkarni Samarth | D | 204582 | 25000 | 28 дек 2022 г. |
| Kulkarni Samarth | D | 369111 | 4634 | 28 дек 2022 г. |
| Kulkarni Samarth | D | 373745 | 20366 | 28 дек 2022 г. |
| Kulkarni Samarth | A | 394111 | 25000 | 28 дек 2022 г. |
| Kulkarni Samarth | D | 0 | 58233 | 06 дек 2022 г. |
| Kulkarni Samarth | A | 369111 | 58233 | 06 дек 2022 г. |
Новостная лента
Why These 3 Nasdaq Stocks Were Glowing Green This Week
The Motley Fool
11 мая 2023 г. в 15:13
A fair number of Nasdaq-listed growth stocks moved higher this week. CRISPR Therapeutics, BioXcel Therapeutics, and Verve Therapeutics were among the biggest winners this week.
Final Trades: Berkshire, Devon Energy & CRISPR Therapeutics
CNBC Television
09 мая 2023 г. в 14:39
The "Halftime Report" traders give their top picks to watch for the second half.
Why CRISPR Therapeutics Stock Is on Fire Today
The Motley Fool
09 мая 2023 г. в 14:25
CRISPR Therapeutics reported 2023 Q1 earnings yesterday. The biotech's Q1 report was full of good news for shareholders.
CRISPR Therapeutics AG (CRSP) Reports Q1 Loss, Tops Revenue Estimates
Zacks Investment Research
08 мая 2023 г. в 19:03
CRISPR Therapeutics AG (CRSP) came out with a quarterly loss of $0.67 per share versus the Zacks Consensus Estimate of a loss of $1.67. This compares to loss of $2.32 per share a year ago.
This Incredible Growth Stock Has All the Hallmarks of a Prototypical Warren Buffett Stock
The Motley Fool
06 мая 2023 г. в 13:00
Warren Buffett has a laser-like focus on owning companies with limited competition, stellar management, and sustainable profits. The rare disease specialist Vertex Pharmaceuticals ticks all of these boxes, despite operating in a fiercely competitive industry.